Aipalolitovorelizumab
Sponsors
Yanqiao Zhang, Harbin Medical University
Conditions
Colorectal Cancer
Phase 2
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Not yet recruitingNCT07229846
Start: 2026-02-28End: 2028-02-29Target: 30Updated: 2026-01-08
A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
Not yet recruitingNCT07229872
Start: 2025-12-31End: 2027-12-31Target: 18Updated: 2025-11-17